Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer
出版年份 2022 全文链接
标题
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-10-11
DOI
10.1016/j.annonc.2022.09.159
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
- (2022) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract GS4-08: Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance
- (2022) Anton Safonov et al. CANCER RESEARCH
- Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer
- (2022) Patricia A Ganz et al. CANCER RESEARCH
- Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients
- (2022) Marion T. van Mackelenbergh et al. EUROPEAN JOURNAL OF CANCER
- OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis
- (2021) Matthew G. Davey et al. EUROPEAN JOURNAL OF CANCER
- Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
- (2021) Ingrid A. Mayer et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
- (2021) N. Harbeck et al. ANNALS OF ONCOLOGY
- Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?
- (2021) Ji-Yeon Kim et al. Frontiers in Oncology
- Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
- (2020) Ainhoa Madariaga et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
- (2020) P.A. Fasching et al. ANNALS OF ONCOLOGY
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- 1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
- (2019) S Domchek et al. ANNALS OF ONCOLOGY
- Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
- (2019) Ana Lluch et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours
- (2018) Ruth Plummer et al. ADVANCES IN THERAPY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy
- (2016) Frederik Marmé et al. EUROPEAN JOURNAL OF CANCER
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
- (2012) N. Mavaddat et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
- (2011) Elizabeth A. Mittendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer
- (2008) Deann P. Atchley et al. JOURNAL OF CLINICAL ONCOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started